

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.

Follow this format for each person. **DO NOT EXCEED FOUR PAGES**

NAME Julie Parsonnet	POSITION TITLE Professor of Medicine and of Health Research and Policy		
eRA COMMONS USER NAME PARSONNET.JULIE			
EDUCATION/TRAINING ( <i>Begin with baccalaureate or other initial professional education, such as</i>			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Harvard-Radcliffe College, Cambridge, MA	A.B.	1979	History and Science
Cornell University Medical College, NYC, NY	M.D.	1983	Medicine
Massachusetts General Hospital, Boston, MA	Intern/Resident	1986	Internal Medicine
Massachusetts General Hospital, Boston, MA	Fellow	1987	Infectious Diseases

**A. Positions and Honors****Positions and Employment**

1987-1989 Centers for Disease Control, Epidemic Intelligence Service Officer, Enteric Diseases Branch

1989-1996 Stanford University, Assistant Professor of Medicine (Infectious Diseases and Geographic Medicine)

1992-1996 Stanford University, Assistant Professor of Health Research and Policy (Epidemiology)

1996-1997 Stanford University, Acting Chief, Division of Infectious Diseases and Geographic Medicine.

1996-2005 Stanford University, Associate Professor of Medicine and of Health Research and Policy

1999-2001 Stanford University, Chief, Division of Infectious Diseases and Geographic Medicine

2001-2006 Stanford University, Senior Associate Dean for Medical Education

2005 - Stanford University, Professor of Medicine and of Health Research and Policy

**Other Professional Experience**

1991-present Ad Hoc Member of numerous NIH study sections and Program Project Reviews

1995-1999 Member, Anti-infective Drugs Advisory Committee, FDA

2001-2004 Member, Vaccine Advisory Committee, FDA

**Selected Honors**

1989 United States Public Health Service Achievement Award

1991 Young Investigators Award, IDSA and Ortho Pharmaceuticals

1998 Member, American Society for Clinical Investigation

1999 Member, American Epidemiologic Society

2000 Induction, Leon G. Smith Infectious Disease Institute Hall of Fame

2001- Listed 2001, 2005, 2007 in "Best Doctors in the U.S."

2005 George DeForest Barnett Endowed Professorship in Medicine

**B. Selected peer-reviewed publications from >100 (in chronological order)**

Parsonnet J, Greene K, Gerber RA, Tauxe R, Vallejo OJ, Blake P. Shigella dysenteriae type 1 infections in U.S. travelers to Mexico, 1988. *Lancet* 1989; ii:543-545.

Strockbine NA, Parsonnet J, Greene KD, Kiehlbauch JA, Wachsmuth IK. Molecular epidemiologic techniques in analysis of epidemic and endemic Shigella dysenteriae type 1 strains. *Journal of Infectious Diseases* 1991; 163:406-408.

Parsonnet J, Friedman GD, Vandersteen DT, Chang Y, Vogelmann JH, Orentreich N, Sibley R. Helicobacter pylori infection and the risk for gastric carcinoma. *New England Journal of Medicine* 1991; 325:1127-1131.

- Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelmann JH, Friedman GD. *Helicobacter pylori* infection and gastric lymphoma. *New England Journal of Medicine* 1994; 330:1267-1271.
- Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schechter GF, Daley CL, Schoolnik GK. The contemporary urban epidemiology of tuberculosis: a population-based study using conventional and molecular methods. *New England Journal of Medicine* 1994; 330:1703-1709.(675)
- Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. *Helicobacter pylori* virulence and genetic geography. *Science*. 1999;284:1328-33.
- Parsonnet J, Shmueli H, Haggerty T. Fecal and oral shedding of *Helicobacter pylori* from healthy, infected adults. *JAMA*. 1999.282:2240-45.
- Rupnow MFT, Shachter RD, Owens DK, Parsonnet J. Using a dynamic transmission model to predict the future of *H. pylori* and associated diseases. *Emerging Infectious Diseases* 2000;6:228-37.
- Rupnow MFT, Shachter RD, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic *Helicobacter pylori* vaccine. *Vaccine*. 2001;20:879-85.
- Shibata A, Parsonnet J, Longacre TA, et al. CagA status of *Helicobacter pylori* infection and p53 gene mutations in gastric adenocarcinoma. *Carcinogenesis*. 2002;23:419-424.
- Mohar A, Ley C, Guarner J, Herrera-Goepfert R, Sanchez Figueroa L, Halperin D, Parsonnet J. Eradication rate of *Helicobacter pylori* in a Mexican population at high risk for gastric cancer and use of serology to assess cure. *Am J Gastroenterol*. 2002;97:2530-5.
- Torres MA, Passaro DJ, Watanabe J, Parsonnet J, Small P, Miyagi X, Rodriguez C, Astete X, Walz S, Gilman RA. No association between *Helicobacter pylori* and *Mycobacterium tuberculosis* infections among gastrointestinal clinic attendees in Lima, Peru. *Journal of Epidemiology and Infection*. 2003;130:87-91.
- Haggerty TD, Shmueli H, Parsonnet J. *Helicobacter pylori* in cathartic stools of subjects with and without hypochlorhydria. *J Med Microbiol*. 2003;52: 189-191.
- Witherell HL, Smith KL, Friedman GD, Ley C, Thom DH, Orentreich N, Vogelmann JH, Parsonnet J. C-reactive protein, *Helicobacter pylori*, *Chlamydia pneumoniae*, cytomegalovirus and risk for myocardial infarction: a prospective study. *Ann Epidemiol* 2003;13:170-177.
- Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Sanchez-Figueroa L, Halperin D, Johnstone I, Parsonnet J. *Helicobacter pylori* eradication and gastric preneoplastic conditions: a randomized double-blind, placebo-controlled trial. *Cancer Epidemiol Biomarkers Prevention*. 2004;13:1-7.
- Perry S, Sanchez L, Yang S, Haggerty TD, Hurst P, Parsonnet J. *Helicobacter pylori* and risk for gastroenteritis. *J Infect Dis*. 2004;190:303-310.
- de Martel C, Llosa AE, Farr SM, Friedman GD, Vogelmann JH, Orentreich N, Corley DA, Parsonnet J. *H. pylori* infection and risk for subsequent adenocarcinoma of the esophagus. *J Infect Dis*. 2005;191:761-7.
- Nguyen MH, Perry S, Parsonnet J. Quantiferon-TB predicts tuberculin skin test in U.S. Foreign-born. *Int J Tuberculosis Lung Dis*. 2005;9:958-91.
- Garg, P, Perry S, Dorn M, Himathongkham S, Hardcastle L, Parsonnet J. Risk of intestinal helminth and protozoan infection in a refugee population. *Am J Trop Med Hygiene*. 1005;73:386-91.
- Perry S, Sanchez ML, Hurst PK, Parsonnet J. Household transmission of gastroenteritis: A community-based study. *Emerging Infectious Diseases*. 2005;11:1093-6.
- Guarner J, Bartlett J, Seitz R, Whistler T, Herrera-Goepfert R, Mohar A, Sanchez ML, Halperin D, Parsonnet J. Cell proliferation and inflammation on biopsy samples with multifocal atrophic gastritis before and 1 year after *Helicobacter pylori* eradication. *Archives of Pathology and Laboratory Medicine*. 1005;129:1451-6..
- Tsai CJ, Perry S, Sanchez L, Parsonnet J. *Helicobacter pylori* infection in different generations of Hispanics in the San Francisco Bay Area. *Am J Epidemiol*. 2005;162:351-7.
- de Martel C, Ratanasopa S, Passaro D, Parsonnet J. Validation of the blood Quininium Resin Test for assessing gastric hypochlorhydria. *Digestive Diseases and Sciences*. 2006;51:84-8.
- Tsai CJ, Herrera-Goepfert R, Tibshiran RJ, Yang S, Mohar A, Guarner J, Parsonnet J. Changes of gene expression in gastric preneoplasia following *Helicobacter pylori* eradication therapy. *Cancer Epidemiology Biomarkers and Prevention* 2006;15:272-80.

- DeMartel C, Parsonnet J. *Helicobacter pylori* infection and gender: a meta-analysis of population-based prevalence surveys. *Digestive Diseases and Sciences* 2006;51(12):2292-301.
- Lentine KL, Parsonnet J, Taylor I, Wrone EM, Lafayette RA. Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients.. *Clin Exp Nephrol* . 2006 Mar;10(1):55-62.
- Perry S, Sanchez ML, Yang S, Haggerty TD, Hurst PK, Perez-Perez G, Parsonnet J . Gastroenteritis and transmission of *Helicobacter pylori* infection in households. *Emerging Infectious Diseases* 2006;12(11):1701-2.
- Solnick, JV, Fong J, Hansen LM, Chang K, Canfield DR, Parsonnet J. Acquisition of *Helicobacter pylori* infection in Rhesus macaques is most consistent with oral-oral transmission. *J Clin Microbiol*. 2006;10:3799-803.
- De Martel C, Haggerty TD, Corley DA, Vogelman JH, Orentreich N, Parsonnet J. Ghrelin and esophageal adenocarcinoma. *Am J Gastroenterol* 2007;102:116-72
- Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Parsonnet J. *Helicobacter pylori* Infection and the risk of Barrett's oesophagus *Gut* 2008;57:726-33.
- Choy M, Switzer P, de Martel C, Parsonnet J. Estimating disease prevalence using census data. *Epidemiology and Infection* 2007 Nov 30:1-8, (epub ahead of print)
- Perry S, Sanchez ML, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON®-TB GOLD In-tube Assay. *Clinical and Vaccine Immunology* 2008;15:425-32.
- De Martel C, Llosa AE, Friedman GD, Vogelman JH, Orentreich N, Stolzenberg-Soloman RZ, Parsonnet J. *Helicobacter pylori* infection and development of pancreatic cancer. *Cancer Epidemiol Biomarkers Prevention* 2008;17:1188-94.
- Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Parsonnet J. *Helicobacter pylori* infection and gastroesophageal reflux disease: a case-control study. *Helicobacter* 2008;13:352-60.
- Chiu C, Grening A, Haggerty T, Kwok T, Kanada K, Louie J, Shigeo Y, Schnurr D, Parsonnet J, Ganem D, DeRisi J. Identification of novel cardioviruses related to Theiler's murine encephalomyelitis viruses in human cases of gastroenteritis and other illnesses. *PNAS*. 2008 In press.
- Greninger A, Runckel C, Chiu C, Haggerty T, Parsonnet J, Ganem D, DeRisi J. Klassevirus—a novel picornavirus in pediatric stool. *Viol. J* 2009;6:82
- Green EP, Borkan JM, Pross SH, Adler SR, Nothnagle M, Parsonnet J, Gruppuso PA. Encouraging scholarship: Medical school programs to promote student inquiry beyond the traditional medical curriculum. *Academic Medicine*. In press.
- Parsonnet J, Gruppuso PA, Kanter S, Boninger M .Required vs. elective research and in-depth scholarship program in the medical school curriculum. *Academic Medicine*. In press.
- Rupnow MFT, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic *Helicobacter pylori* vaccine in the United States. *J Infect Dis*. In press.
- Perry S, de Jong BC, Sanchez ML, Yang S, Hill PC, Adegbola RA, Parsonnet J. *Helicobacter pylori* and the role of natural infections in host immunity to tuberculosis. *PLOS One* . In press.

## C. Research Support

### Active Projects

R01 HD063142 (Parsonnet ) 10//109 – 9/30/14 (estimated) NIH  
Transformative R01: Childhood infection and prevention of obesity

The objective is to see whether frequent, chronic and/or severe prenatal and childhood infection prevent weight gain, overweight and obesity in children.

R01 AI042801 (Parsonnet ) 3/01/06 –2/28/11 NIH  
Epidemiology of Helicobacter Pylori Transmission

The objective of the research is to better characterize how infections interact within humans. Specifically, to see how host response to gastric infection with *H. pylori* varies in the setting of strong chronic inducers of Th1 response (*M. tuberculosis*) or Th2 response (intestinal helminths).

Gates Grand Challenge Exploration Grant (Solnick) 12/1/08 – 11/31/09  
Prevention of Active Tuberculosis by Infection with *Helicobacter pylori*

The objective of this grant is to evaluate the role of *H. pylori* in enhancing the immune response against tuberculosis. Studies are performed in monkeys (Solnick) and humans (Parsonnet).

Role: Co-investigator

Institute for Infection, Transplant and Immunity Seed Grant (Parsonnet) 3/15/2008 – 3/14/2010  
Stanford University

Development of a microbial antigen array for multiplex, longitudinal analysis of exposure to infectious agents.

The primary aims of this project are To select microbial antigens (viral, bacterial, fungal and parasitic) for inclusion in a microbial antigen array that can be used to investigate etiology of chronic diseases and to develop and test the performance characteristics of this array

U19 AI057229 (Arvin) NIH Cooperative Center for Translational Research on Human Immunology and Biodefense The Stanford/Packard Vaccine Center 11/1/07 – 10/31/09

Development of a cell proliferation assay for assessing cell-mediated immunity to infectious diseases in type-2 diabetics

The aim of our pilot study is to establish methods for assessing cell proliferation in a study of BCG vaccination in diabetics and non-diabetics.

Role: PI of pilot

### **COMPLETED RESEARCH SUPPORT**

R01 DK53689 (Parsonnet) NIH 9/30/97 – 9/29/08

Clinical Experiment of *Helicobacter Pylori* Transmission

To determine whether *H. pylori* infection is permissive of gastrointestinal infection with acid sensitive organism and whether gastrointestinal infection that leads to diarrhea and vomiting increases shedding of *H. pylori*.

R01 CA95946 (Parsonnet) National Cancer Institute, NIH 9/30/02 – 8/29/07

GIS for Extant Data: Modeling *H. Pylori* and GI Tumors

To see if GIS can be used to track *H. pylori*-infection related tumors.

M01 RR000070 (Parsonnet)

8/1/06 – 12/1/2007

No effort

General Clinical Research Center,

CRFF Grant

\$20,000

Effect of Diabetes on Cytokine Response to BCG Vaccination

This is a pilot grant to establish methods of detecting cytokines in PBMC stimulated with antigens from *M. tuberculosis* pre- and post-BCG vaccination

R01 RR14298-01A (Solnick) NIH/University of California, Davis 9/12/01 - 8/31/07

Transmission of *H. Pylori* in the Rhesus Monkey

The purpose of this study was to elucidate how *H. pylori* is transmitted among primates as a model for transmission among humans.

Role: Co-investigator

Thrasher Research Fund (Parsonnet)

5/1/04 – 4/30/07

Immunoepidemiology of Tuberculosis

Principal Investigator/Program Director (Last, First, Middle): Parsonnet, Julie

The purpose of this study was to assess the Quantiferon-Gold assay among recent immigrants, including children, and to assess the affects of *H. pylori* infection on assay performance.